水飞蓟素与左卡尼汀对非酒精性脂肪性肝病的临床研究  

Clinical effect of silymarin combined with levocarnitine on non-alcoholic fatty liver disease

作　　者：刘震[1] 沈洪亮[1] 张建表[1] 

机构地区：[1]上海市浦东新区人民医院消化内科,上海201200

出　　处：《中国当代医药》2009年第7期19-20,共2页China Modern Medicine

摘　　要：目的:观察水飞蓟素联合左卡尼汀治疗非酒精性脂肪肝的疗效。方法:将68例脂肪肝患者随机分为治疗组与对照组,治疗组34例给予水飞蓟素联合左卡尼汀治疗8周。对照组34例使用水飞蓟素治疗8周,治疗前后检查各组血清转氨酶、血脂及肝脏超声。结果:水飞蓟素联合左卡尼汀治疗组总有效率91.1%(31例),明显优于对照组且差异有统计学意义(P<0.05)。结论:水飞蓟素联合左卡尼汀治疗非酒精性脂肪性肝病患者具有良好作用。Objective： To assess the therapeutic effect of silymafin combined with levocarnitine on non-alcoholic fatty liver disease（NAFL）. Methods： Sixty-eight patients with NAFL were randomly assigned 34 cases to receive silymarin combined with levocarnitine（8 weeks） as treatment group. Control group 34 cases were treated with silymarin（8 weeks）. Before and af- ter treatment serum transaminase levels, triglyceride, cholesterol and liver uhrasonography were detected pre-and pors- treatment. Results： The total effective rate was 91.1% in treatment group, significantly higher than control group after treat ment（P〈0.05）. Conclusion： Silymariu combined with levoearnitine have a significant therapeutic effect on the treatment of NAFL.

关 键 词：水飞蓟素 左卡尼汀 非酒精性脂肪性肝病 

分 类 号：R575[医药卫生—消化系统]